

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/58, 9/72, A61K 38/49</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/05257</b> <b>(43) International Publication Date:</b> 13 February 1997 (13.02.97)
<b>(21) International Application Number:</b> PCT/US96/12044 <b>(22) International Filing Date:</b> 19 July 1996 (19.07.96)  <b>(30) Priority Data:</b> 08/509,208 31 July 1995 (31.07.95) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/509,208 (CIP) Filed on 31 July 1995 (31.07.95)  <b>(71) Applicant (for all designated States except US):</b> CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).  <b>(71)(72) Applicants and Inventors:</b> ROSENBERG, Steven [US/US]; 2323 Bywood Drive, Oakland, CA 94602 (US). SPEAR, Kerry, L. [US/US]; 5832 Colton Boulevard, Oakland, CA 94611 (US). VALERIO, Robert [AU/AU]; 17 Homestead Road, Cranbourne, VIC 3977 (AU). BRAY, Andrew [AU/AU]; 48 Western Road, Boronia, VIC 3155 (AU).	<b>(74) Agents:</b> CHUNG, Ling, Fong et al.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY  <b>(57) Abstract</b>  Effective urokinase-type plasminogen activator receptor antagonists have sequences selected from the group LNFGQYLWYT, LCFG-CYLWYT, LNFGCYLWCT, LNFGQYLnAYT, LNFdSQYLWYT, LCFGCYLWY, LNFdSQYLnAYT, LNFGdCYLWCT, LCFdSCYLWYT, LCFdSCYLnAYT, LNFdSCYLWCT, or active analogs or active portions thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Peptide Analog Inhibitors of Urokinase Receptor Activity

### Description

5

#### Technical Field

This invention relates to the fields of cellular biology and protein expression. More particularly, the invention relates to peptide and peptide analog ligands of the urokinase plasminogen activator receptor, and methods for preparing the same.

10

#### Background of the Invention

Urokinase-type plasminogen activator (uPA) is a multidomain serine protease, having a catalytic "B" chain (amino acids 144-411), and an amino-terminal fragment ("ATF", aa 1-143) consisting of a growth factor-like domain (4-43) and a kringle (aa 47-135). The uPA kringle appears to bind heparin, but not fibrin, lysine, or aminohexanoic acid. The growth factor-like domain bears some similarity to the structure of epidermal growth factor (EGF), and is thus also referred to as an "EGF-like" domain. The single chain pro-uPA is activated by plasmin, cleaving the chain into the two chain active form, which is linked together by a disulfide bond.

20

uPA binds to its specific cell surface receptor (uPAR). The binding interaction is apparently mediated by the EGF-like domain (S.A. Rabbani *et al.*, J Biol Chem (1992) 267:14151-56). Cleavage of pro-uPA into active uPA is accelerated when pro-uPA and plasminogen are receptor-bound. Thus, plasmin activates pro-uPA, which in turn activates more plasmin by cleaving plasminogen. This positive feedback cycle is apparently limited to the receptor-based proteolysis on the cell surface, since a large excess of protease inhibitors is found in plasma, including  $\alpha_2$  antiplasmin, PAI-1 and PAI-2.

25

Plasmin can activate or degrade extracellular proteins such as fibrinogen, fibronectin, and zymogens. Plasminogen activators thus can regulate extracellular proteolysis, fibrin clot lysis, tissue remodeling, developmental cell migration, inflammation, and metastasis. Accordingly, there is great interest in developing uPA inhibitors and uPA receptor antagonists. E. Appella *et al.*, J Biol Chem (1987) 262:4437-40, determined that receptor

30

- 2 -

binding activity is localized in the EGF-like domain, and that residues 12-32 appear to be critical for binding. The critical domain alone (uPA<sub>12-32</sub>) bound uPAR with an affinity of 40 nM (about 100 fold less than intact ATF).

5 S.A. Rabbani *et al.*, *supra*, disclosed that the EGF-like domain is fucosylated at Thr<sub>18</sub>, and reported that fucosylated EGF-like domain (uPA<sub>4-43</sub>, produced by cleavage from pro-uPA) was mitogenic for an osteosarcoma cell line, SaOS-2. In contrast, non-fucosylated EGF-like domain bound uPAR with an affinity equal to the fucosylated EGF-like domain, but exhibited no mitogenic activity. Non-fucosylated EGF-like domain competed for binding to uPAR with fucosylated EGF-like domain, and reduced the mitogenic activity  
10 observed. Neither fucosylated nor non-fucosylated EGF-like domain was mitogenic in U937 fibroblast cells.

R.J. Goodson *et al.*, Proc Natl Acad Sci USA (1994) 91:7129-33 disclosed a number of peptide sequences which bind to the human uPA receptor with micromolar affinities.

15

### Disclosure of the Invention

One aspect of the invention is the set of polypeptides disclosed herein, and analogs thereof, which bind to the urokinase plasminogen activator receptor and inhibit the receptor binding activity of urokinase-type plasminogen activator.

20

Another aspect of the invention is a method for treating a urokinase-modulated disorder, such as cancer and metastasis, by administering an effective amount of a peptide of the invention or an analog thereof.

Another aspect of the invention is a composition suitable for treating a urokinase-modulated disorder, comprising an effective amount of a peptide of the invention  
25 or an analog thereof in combination with a pharmaceutically acceptable excipient.

### Modes of Carrying Out The Invention

#### A. Definitions

The term "huPA" refers specifically to human urokinase-type plasminogen activator.  
30 The "EGF-like domain" is that portion of the huPA molecule responsible for mediating huPA binding to its receptor (uPAR). The EGF-like domain, sometimes called the growth factor-

- 3 -

like domain ("GFD"), is located within the first 48 residues of huPA. The critical residues (essential for binding activity) have been localized to positions 12-32, although a peptide containing only those residues does not exhibit a binding affinity high enough to serve as a useful receptor antagonist.


5 "Peptides of the invention" and "huPAR antagonist peptides" have one of the following sequences:

10 LNFGQYLWYT (SEQ ID NO:1),  
 LCFGCYLWYT (SEQ ID NO:2),  
 LNFGCYLWCT (SEQ ID NO:3),  
 LNFGQYL<sub>n</sub>AYT (SEQ ID NO:4),  
 LNFdSQYLWYT (SEQ ID NO:5),  
 LCFGCYLWY (SEQ ID NO:6),  
 LNFdSQYL<sub>n</sub>AYT (SEQ ID NO:7),  
 LNFGdCYLWCT (SEQ ID NO:8),  
 15 LCFdSCYLWYT (SEQ ID NO:9),  
 LCFdSCYL<sub>n</sub>AYT (SEQ ID NO:10),  
 LNFdSCYLWCT (SEQ ID NO:11),

where dS denotes D-Ser, dC denotes D-Cys, and nA denotes 1-naphthylalanine.

20 The term "active analog" refers to a polypeptide differing from the sequence of one of the peptides of the invention, or an active portion thereof by 1-3 amino acids, but which still exhibits a  $K_d \leq 250$  nM with huPAR. The differences are preferably conservative amino acid substitutions, in which an amino acid is replaced with another amino acid or amino acid analog of similar character. For example, the following substitutions are  
 25 considered "conservative" of natural amino acids: Gly  $\leftrightarrow$  Ala; Val  $\leftrightarrow$  Ile  $\leftrightarrow$  Leu; Asp  $\leftrightarrow$  Glu; Lys  $\leftrightarrow$  Arg; Asn  $\leftrightarrow$  Gln; and Phe  $\leftrightarrow$  Trp  $\leftrightarrow$  Tyr. Conservative analog substitutions include substitution of D-isomers for L-isomers, phenylglycine for phenylalanine, 1-naphthylalanine for tryptophan, and the like. Nonconservative changes are generally substitutions of one of the above amino acids with an amino acid from a different group (*e.g.*,  
 30 substituting Asn for Glu), or substituting Cys, Met, His, or Pro for any of the above amino acids.

The term "fusion protein" refers to a protein of the form:



in which at least one of  $X_1$  and  $X_2$  is a protein or polypeptide, (peptide) is a peptide of the  
 35 invention or an active analog thereof, and  $n$  is an integer from 1 to 100.  $X_1$  and  $X_2$  may be

- 4 -

the same or different, and may be portions of the same protein (*e.g.*, the peptide may be inserted at an internal position within the primary sequence of another protein).  $X_1$  and  $X_2$  may be selected to improve expression of the peptide/fusion protein, to enhance purification, and/or to provide a biological activity. The peptides of the invention may be the same or  
 5 different, and may be separated by peptide spacers (*e.g.*, if it is desired to prepare a fusion protein capable of crosslinking huPAR on the cell surface). Alternatively, the peptides may be separated by proteolytic cleavage sites, to facilitate cleavage of the fusion protein into individual active peptides.

The term "conventional amino acid" refers to the amino acids alanine (A),  
 10 cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine (V), tryptophan (W), and tyrosine (Y).

The term "nonconventional amino acid" refers to amino acids other than  
 15 conventional amino acids. Presently preferred nonconventional amino acids are:

Nle = L-norleucine;	Aabu = $\alpha$ -aminobutyric acid;
Hphe = L-homophenylalanine;	Nva = L-norvaline;
Gabu = $\gamma$ -aminobutyric acid;	Dala = D-alanine;
Dcys = D-cysteine;	Dasp = D-aspartic acid;
20 Dglu = D-glutamic acid;	Dphe = D-phenylalanine;
Dhis = D-histidine;	Dile = D-isoleucine;
Dlys = D-lysine;	Dleu = D-leucine;
Dmet = D-methionine;	Dasn = D-asparagine;
Dpro = D-proline;	Dgln = D-glutamine;
25 Darg = D-arginine;	Dser = D-serine;
Dthr = D-threonine;	Dval = D-valine;
Dtrp = D-tryptophan;	Dtyr = D-tyrosine;
Dorn = D-ornithine;	Aib = aminoisobutyric acid;
Etg = L-ethylglycine;	Tbug = L- <i>t</i> -butylglycine;
30 Pen = penicillamine;	Anap = 1-naphthylalanine;
Chexa = cyclohexylalanine;	Cpen = cyclopentylalanine;
Cpro = aminocyclopropane carboxylate;	Norb = aminonorbornylcarboxylate;
Mala = L- $\alpha$ -methylalanine;	Mcys = L- $\alpha$ -methylcysteine;
Masp = L- $\alpha$ -methylaspartic acid;	Mglu = L- $\alpha$ -methylglutamic acid;
35 Mphe = L- $\alpha$ -methylphenylalanine;	Mhis = L- $\alpha$ -methylhistidine;
Mile = L- $\alpha$ -methylisoleucine;	Mlys = L- $\alpha$ -methyllysine;
Mleu = L- $\alpha$ -methylleucine;	Mmet = L- $\alpha$ -methylmethionine;
Masn = L- $\alpha$ -methylasparagine;	Mpro = L- $\alpha$ -methylproline;
Mgln = L- $\alpha$ -methylglutamine;	Marg = L- $\alpha$ -methylarginine;

Mser = L- $\alpha$ -methylserine;  
 Mval = L- $\alpha$ -methylvaline;  
 Mtyr = L- $\alpha$ -methyltyrosine;  
 Mnle = L- $\alpha$ -methylnorleucine;  
 5 Mnva = L- $\alpha$ -methylnorvaline;  
 Metg = L- $\alpha$ -methylethylglycine;  
 Maib =  $\alpha$ -methylaminoisobutyric acid;  
 Mpen =  $\alpha$ -methylpenicillamine;  
 Mchexa =  $\alpha$ -methylcyclohexylalanine;  
 10 Dmala = D- $\alpha$ -methylalanine;  
 Dmcys = D- $\alpha$ -methylcysteine;  
 Dmglu = D- $\alpha$ -methylglutamic acid;  
 Dmhis = D- $\alpha$ -methylhistidine;  
 Dmlys = D- $\alpha$ -methyllysine;  
 15 Dmmet = D- $\alpha$ -methylmethionine;  
 Dmpro = D- $\alpha$ -methylproline;  
 Dmarg = D- $\alpha$ -methylarginine;  
 Dmthr = D- $\alpha$ -methylthreonine;  
 Dmtrp = D- $\alpha$ -methyltryptophan;  
 20 Nmala = L-N-methylalanine;  
 Nmasp = L-N-methylaspartic acid;  
 Nmphe = L-N-methylphenylalanine;  
 Nmleu = L-N-methylisoleucine;  
 Nmleu = L-N-methylleucine;  
 25 Nmasn = L-N-methylasparagine;  
 Nmglu = L-N-methylglutamine;  
 Nmser = L-N-methylserine;  
 Nmval = L-N-methylvaline;  
 Nmtyr = L-N-methyltyrosine;  
 30 Nmnle = L-N-methylnorleucine;  
 Nmnva = L-N-methylnorvaline;  
 Nmetg = L-N-methylethylglycine;  
 Nmcpen = N-methylcyclopentylalanine;  
 Nmpen = N-methylpenicillamine;  
 35 Nmaib = N-methylaminoisobutyric acid;  
 Dnmala = D-N-methylalanine;  
 Dnmcys = D-N-methylcysteine;  
 Dnmglu = D-N-methylglutamic acid;  
 Dnmhis = D-N-methylhistidine;  
 40 Dnmlys = D-N-methyllysine;  
 Dnmmet = D-N-methylmethionine;  
 Dnmpro = D-N-methylproline;  
 Dnmarg = D-N-methylarginine;  
 Dnmthr = D-N-methylthreonine;  
 45 Dnmtrp = D-N-methyltryptophan;  
 Nala = N-methylglycine (sarcosine);

Mthr = L- $\alpha$ -methylthreonine;  
 Mtrp = L- $\alpha$ -methyltryptophan;  
 Morn = L- $\alpha$ -methylornithine;  
 Maabu =  $\alpha$ -amino- $\alpha$ -methylbutyric acid;  
 Mhphe = L- $\alpha$ -methylhomophenylalanine;  
 Mgabu =  $\alpha$ -methyl- $\gamma$ -aminobutyric acid;  
 Mtbug = L- $\alpha$ -methyl-*t*-butylglycine;  
 Manap =  $\alpha$ -methyl- $\alpha$ -naphthylalanine;  
 Mcpen =  $\alpha$ -methylcyclopentylalanine;  
 Dmorn = D- $\alpha$ -methylornithine;  
 Dmasp = D- $\alpha$ -methylaspartic acid;  
 Dmphe = D- $\alpha$ -methylphenylalanine;  
 Dmile = D- $\alpha$ -methylisoleucine;  
 Dmleu = D- $\alpha$ -methylleucine;  
 Dmasn = D- $\alpha$ -methylasparagine;  
 Dmgln = D- $\alpha$ -methylglutamine;  
 Dmser = D- $\alpha$ -methylserine;  
 Dmval = D- $\alpha$ -methylvaline;  
 Dmtyr = D- $\alpha$ -methyltyrosine;  
 Nmcys = L-N-methylcysteine;  
 Nmglu = L-N-methylglutamic acid;  
 Nmhis = L-N-methylhistidine;  
 Nmlys = L-N-methyllysine;  
 Nmmet = L-N-methylmethionine;  
 Nmchexa = N-methylcyclohexylalanine;  
 Nmarg = L-N-methylarginine;  
 Nmthr = L-N-methylthreonine;  
 Nmtrp = L-N-methyltryptophan;  
 Nmorn = L-N-methylornithine;  
 Nmaabu = N-amino- $\alpha$ -methylbutyric acid;  
 Nmhphe = L-N-methylhomophenylalanine;  
 Nmgabu = N-methyl- $\gamma$ -aminobutyric acid;  
 Nmtbug = L-N-methyl-*t*-butylglycine;  
 Nmanap = N-methyl- $\alpha$ -naphthylalanine;  
 Naeg = N-(2-aminoethyl)glycine;  
 Dnmorn = D-N-methylornithine;  
 Dnmasp = D-N-methylaspartic acid;  
 Dnmphe = D-N-methylphenylalanine;  
 Dnmile = D-N-methylisoleucine;  
 Dnmleu = D-N-methylleucine;  
 Dnmasn = D-N-methylasparagine;  
 Dnmglu = D-N-methylglutamine;  
 Dnmser = D-N-methylserine;  
 Dnmval = D-N-methylvaline;  
 Dnmtyr = D-N-methyltyrosine;  
 Nasp = N-(carboxymethyl)glycine;

- Nglu = N-(2-carboxyethyl)glycine;  
 Nhhis = N-(imidazolethyl)glycine;  
 Nlys = N-(4-aminobutyl)glycine;  
 Nmet = N-(2-methylthioethyl)glycine;  
 5 Nasn = N-(carbamylmethyl)glycine;  
 Nval = N-(1-methylethyl)glycine;  
 Nhtrp = N-(3-indolylethyl)glycine;  
 Nthr = N-(1-hydroxyethyl)glycine;  
 Norm = N-(3-aminopropyl)glycine;  
 10 Ncbut = N-cyclobutylglycine;  
 Nchep = N-cycloheptylglycine;  
 Ncdec = N-cyclodecylglycine;  
 Ncdod = N-cyclododecylglycine;  
 Nbhe = N-(3,3-diphenylpropyl)glycine;  
 15 Nnbhm = N-(N-(2,2-diphenylethyl)carbamylmethyl)glycine;  
 Nnbhe = N-(N-(3,3-diphenylpropyl)carbamylmethyl)glycine; and  
 Nbmc = 1-carboxy-1-(2,2-diphenylethylamino)cyclopropane.
- Nphe = N-benzylglycine;  
 Nile = N-(1-methylpropyl)glycine;  
 Nleu = N-(2-methylpropyl)glycine;  
 Nhser = N-(hydroxyethyl)glycine;  
 Nglu = N-(2-carbamylethyl)glycine;  
 Narg = N-(3-guanidinopropyl)glycine;  
 Nhtrp = N-(*p*-hydroxyphenethyl)glycine;  
 Ncys = N-(thiomethyl)glycine; and  
 Ncpro = N-cyclopropylglycine;  
 Nchex = N-cyclohexylglycine;  
 Ncoct = N-cyclooctylglycine;  
 Ncund = N-cycloundecylglycine;  
 Nbhbm = N-(2,2-diphenylethyl)glycine;

The term "expression vector" refers to an oligonucleotide which encodes the huPAR antagonist polypeptide of the invention and provides the sequences necessary for its expression in the selected host cell. Expression vectors will generally include a transcriptional promoter and terminator, or will provide for incorporation adjacent to an endogenous promoter. Expression vectors will usually be plasmids, further comprising an origin of replication and one or more selectable markers. However, expression vectors may alternatively be viral recombinants designed to infect the host, or integrating vectors designed to integrate at a preferred site within the host's genome. Expression vectors may further comprise an oligonucleotide encoding a signal leader polypeptide. When "operatively connected", the huPAR antagonist is expressed downstream and in frame with the signal leader, which then provides for secretion of the huPAR antagonist polypeptide by the host to the extracellular medium. The presently preferred signal leader is the *Saccharomyces cerevisiae* a-factor leader (particularly when modified to delete extraneous Glu-Ala sequences).

The term "transcriptional promoter" refers to an oligonucleotide sequence which provides for regulation of the DNA → mRNA transcription process, typically based on temperature, or the presence or absence of metabolites, inhibitors, or inducers. Transcriptional promoters may be regulated (inducible/repressible) or constitutive. Yeast glycolytic enzyme promoters are capable of driving the transcription and expression of heterologous proteins to high levels, and are particularly preferred. The presently preferred promoter is



the hybrid ADH2/GAP promoter described in Tekamp-Olson *et al.*, US 4,876,197 (incorporated herein by reference), comprising the *S. cerevisiae* glyceraldehyde-3-phosphate dehydrogenase promoter in combination with the *S. cerevisiae* alcohol dehydrogenase II upstream activation site.

5           The term "host" refers to a yeast cell suitable for expressing heterologous polypeptides. There are a variety of suitable genera, such as *Saccharomyces*, *Schizosaccharomyces*, *Kluveromyces*, *Pichia*, *Hansenula*, and the like. Presently preferred are yeast of the *Saccharomyces* genus, particularly *Saccharomyces cerevisiae*.

          The term "huPA-mediated disorder" refers to a disease state or malady which is  
10   caused or exacerbated by a biological activity of huPA. The primary biological activity exhibited is plasminogen activation. Disorders mediated by plasminogen activation include, without limitation, inappropriate angiogenesis (*e.g.*, diabetic retinopathy, corneal angiogenesis, Kaposi's sarcoma, and the like), metastasis and invasion by tumor cells, and chronic inflammation (*e.g.*, rheumatoid arthritis, emphysema, and the like). Fucosylated ATF  
15   or EGF-like domain are also mitogenic for tumor cells, which sometimes self-activate in an autocrine mechanism. Accordingly, the huPAR antagonist of the invention is effective in inhibiting the proliferation of huPA-activated tumor cells.

          The term "effective amount" refers to an amount of huPAR antagonist polypeptide sufficient to exhibit a detectable therapeutic effect. The therapeutic effect may include,  
20   for example, without limitation, inhibiting the growth of undesired tissue or malignant cells, inhibiting inappropriate angiogenesis, limiting tissue damage caused by chronic inflammation, and the like. The precise effective amount for a subject will depend upon the subject's size and health, the nature and severity of the condition to be treated, and the like. Thus, it is not possible to specify an exact effective amount in advance. However, the effective amount for  
25   a given situation can be determined by routine experimentation based on the information provided herein.

          The term "pharmaceutically acceptable" refers to compounds and compositions which may be administered to mammals without undue toxicity. Exemplary pharmaceutically acceptable salts include mineral acid salts such as hydrochlorides, hydrobromides,  
30   phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.

## B. General Method

The peptides of the invention may be synthesized by standard chemical methods, such as solid phase peptide synthesis. Alternatively, if desired, the peptides composed of naturally-occurring amino acids may be expressed in an appropriate host, preferably as part of a fusion protein. Peptides prepared as part of a fusion protein are preferably expressed in a host cell. Presently preferred hosts are yeasts, particularly *Saccharomyces*, *Schizosaccharomyces*, *Kluveromyces*, *Pichia*, *Hansenula*, and the like, especially *S. cerevisiae*. Strains MB2-1 and AB110 are presently preferred, as are strains JSC302 and JSC308 (for fusion protein constructs).

The expression vector is constructed according to known methods, and typically comprises a plasmid functional in the selected host. The oligonucleotide encoding the peptide or fusion protein will generally be synthesized chemically, or cloned from a suitable source (e.g., from a bacteriophage library). Stable plasmids generally require an origin of replication (such as the yeast 2 $\mu$  ori), and one or more selectable markers (such as antibiotic resistance) which can be used to screen for transformants and force retention of the plasmid. The vector should provide a promoter which is functional in the selected host cell, preferably a promoter derived from yeast glycolytic enzyme promoters such as GAPDH, GAL, and ADH2. These promoters are highly efficient, and can be used to drive expression of heterologous proteins up to about 10% of the host cell weight. The presently preferred promoter is a hybrid ADH2/GAP promoter comprising the *S. cerevisiae* glyceraldehyde-3-phosphate dehydrogenase promoter in combination with the *S. cerevisiae* alcohol dehydrogenase II upstream activation site.

The expression vector should ideally provide a signal leader sequence between the promoter and the huPAR antagonist polypeptide sequence. The signal leader sequence provides for translocation of the huPAR antagonist polypeptide through the endoplasmic reticulum and export from the cell into the extracellular medium, where it may be easily harvested. There are a number of signal leader sequences known that are functional in yeast. Presently preferred are the yeast  $\alpha$ -factor leader (see U.S. 4,751,180, incorporated herein by reference).

Alternatively, the vector may provide for integration into the host genome, as is described by Shuster, PCT WO92/01800, incorporated herein by reference.

Transformations into yeast can be carried out according to the method of A. Hinnen *et al.*, Proc Natl Acad Sci USA (1978) 75:1929-33, or H. Ito *et al.*, J Bacteriol

5 (1983) 153:163-68. After DNA is taken up by the host cell, the vector integrates into the yeast genome at one or more sites homologous to its targeting sequence. It is presently preferred to linearize the vector by cleaving it within the targeting sequence using a restriction endonuclease, as this procedure increases the efficiency of integration.

Following successful transformations, the number of integrated sequences may be  
10 increased by classical genetic techniques. As the individual cell clones can carry integrated vectors at different locations, a genetic cross between two appropriate strains followed by sporulation and recovery of segregants can result in a new yeast strain having the integrated sequences of both original parent strains. Continued cycles of this method with other  
15 integratively transformed strains can be used to further increase the copies of integrated plasmids in a yeast host strain. One may also amplify the integrated sequences by standard techniques, for example by treating the cells with increasing concentrations of copper ions (where a gene for copper resistance has been included in the integrating vector).

Correct ligations for plasmid construction may be confirmed by first transforming  
20 *E. coli* strain MM294 obtained from *E. coli* Genetic Stock Center, CGSC #6135, or other suitable host with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or using other markers depending on the plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of D.B. Clewell *et al.*, Proc Natl Acad Sci USA (1969) 62:1159, optionally following chloramphenicol amplification (D.B. Clewell, J Bacteriol (1972)  
25 110:667). Isolated DNA is analyzed by restriction mapping and/or sequenced by the dideoxy method of F. Sanger *et al.*, Proc Natl Acad Sci USA (1977) 74:5463 as further described by Messing *et al.*, Nucl Acids Res (1981) 9:309, or by the method of Maxam and Gilbert, Meth Enzymol (1980) 65:499.

Fusion proteins may be prepared by the methods described above. One may  
30 improve expression of peptides by expressing them as fusion proteins with a well-expressed protein leader or fusion partner. For example, Cu/Zn superoxide dismutase (SOD) is highly-

expressed in yeast when used as a fusion protein leader. See Cousens *et al.*, US 4,751,180, incorporated herein by reference in full. Other suitable fusion partners include  $\beta$ -galactosidase, human IgG antibody fragments (*e.g.*, Fc fragments), ubiquitin, and the like.

Additionally, one may include secretion leaders, such as the yeast  $\alpha$ -factor leader or bacterial

5. OmpA leader, to direct secretion of the fusion protein to the extracellular medium. One may also employ fusion partners which will impart a biological activity to the fusion protein. For example, one may use a cytotoxic protein such as ricin in order to kill cells bearing huPAR.

- huPAR antagonist polypeptides, active portions, active analogs, active peptoid analogs, and fusion proteins (collectively "antagonists") may be assayed for activity by
- 10 methods known in the art. For example, the methods provided in the examples below, and in R.J. Goodson *et al.*, Proc Natl Acad Sci USA (1994) 91:7129-33 are suitable. Additionally, active analogs may be screened conveniently and efficiently by following the method of H.M. Geysen *et al.*, US 4,708,871. Geysen described a method for synthesizing a set of overlapping oligopeptides derived from any selected protein (*e.g.*, aa<sub>1</sub>-aa<sub>7</sub>, aa<sub>2</sub>-aa<sub>8</sub>, aa<sub>3</sub>-aa<sub>9</sub>, *etc.*)
- 15 bound to a solid phase array of pins, with a unique oligopeptide on each pin. The pins are arranged to match the format of a 96-well microtiter plate, permitting one to assay all pins simultaneously, *e.g.*, for binding to a labeled ligand. Using this method, one may readily determine the binding affinity for the ligand for every possible subset of consecutive conventional and/or nonconventional amino acids presented in any selected antagonist. One
- 20 may assay competition of the antagonist against native huPA for cell surface receptor binding. Competition for the receptor correlates with inhibition of huPA biological activity. One may assay huPAR antagonists for anti-mitogenic activity on appropriate tumor cell lines, such as the osteosarcoma cell line SaOS-2 described in the art. Inhibition of mitogenic activity may be determined by comparing the uptake of <sup>3</sup>H-T in osteosarcoma cells treated
- 25 with the antagonist against controls. One may also assay huPAR antagonists for anti-invasive activity on appropriate tumor cell lines, such as HOC-1 and HCT116 (W. Schlechte *et al.*, Cancer Comm (1990) 2:173-79; H. Kobayashi *et al.*, Brit J Cancer (1993) 67:537-44).

- huPAR antagonists are administered orally, topically, or by parenteral means,
- 30 including subcutaneous and intramuscular injection, implantation of sustained release depots, intravenous injection, intranasal administration, and the like. When used to treat tumors, it

may be advantageous to apply the huPAR antagonist peptide directly to the site, *e.g.*, during surgery to remove the bulk of the tumor. Accordingly, huPAR antagonists may be administered as a pharmaceutical composition comprising a huPAR antagonist in combination with a pharmaceutically acceptable excipient. Such compositions may be aqueous solutions, emulsions, creams, ointments, suspensions, gels, liposomal suspensions, and the like. Suitable excipients include water, saline, Ringer's solution, dextrose solution, and solutions of ethanol, glucose, sucrose, dextran, mannose, mannitol, sorbitol, polyethylene glycol (PEG), phosphate, acetate, gelatin, collagen, Carbopol®, vegetable oils, and the like. One may additionally include suitable preservatives, stabilizers, antioxidants, antimicrobials, and buffering agents, for example, BHA, BHT, citric acid, ascorbic acid, tetracycline, and the like. Cream or ointment bases useful in formulation include lanolin, Silvadene® (Marion), Aquaphor® (Duke Laboratories), and the like. Other topical formulations include aerosols, bandages, and other wound dressings. Alternatively, one may incorporate or encapsulate the huPAR antagonist in a suitable polymer matrix or membrane, thus providing a sustained-release delivery device suitable for implantation near the site to be treated locally. Other devices include indwelling catheters and devices such as the Alzet® minipump. Ophthalmic preparations may be formulated using commercially available vehicles such as Sorbi-care® (Allergan), Neodecadron® (Merck, Sharp & Dohme), Lacrilube®, and the like, or may employ topical preparations such as that described in US 5,124,155, incorporated herein by reference. Further, one may provide a huPAR antagonist in solid form, especially as a lyophilized powder. Lyophilized formulations typically contain stabilizing and bulking agents, for example human serum albumin, sucrose, mannitol, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co.).

The amount of huPAR antagonist required to treat any particular disorder will of course vary depending upon the nature and severity of the disorder, the age and condition of the subject, and other factors readily determined by one of ordinary skill in the art. The appropriate dosage may be determined by one of ordinary skill by following the methods set forth below in the examples. As a general guide, about 0.010 mg/Kg to about 500 mg/Kg huPAR antagonist administered *i.v.* or subcutaneously is effective for inhibiting tissue damage due to chronic inflammation. For treating corneal angiogenesis, huPAR antagonist

- 12 -

may be administered locally in a gel or matrix at a concentration of about 0.01 mg/Kg to about 50 mg/Kg.

### C. Examples

5           The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.

#### Example 1

##### (Peptide Synthesis)

10           The following peptides were synthesized using the "pin method" and supplied by Chiron Mimotopes (Melbourne, Australia):

15           LNFGQYLWYT (SEQ ID NO:1),  
            LCFGCYLWYT (SEQ ID NO:2),  
            LNFGCYLWCT (SEQ ID NO:3),  
            LNFGQYL<sub>n</sub>AYT (SEQ ID NO:4),  
            LNFdSQYLWYT (SEQ ID NO:5),  
            LCFGCYLWY (SEQ ID NO:6),  
            LNFdSQYL<sub>n</sub>AYT (SEQ ID NO:7),  
            LNFGdCYLWCT (SEQ ID NO:8),  
20           LCFdSCYLWYT (SEQ ID NO:9),  
            LCFdSCYL<sub>n</sub>AYT (SEQ ID NO:10),  
            LNFdSCYLWCT (SEQ ID NO:11),

            where dS denotes D-Ser, dC denotes D-Cys, and nA denotes 1-naphthylalanine. All peptides were purified by preparative reverse phase HPLC and concentrations determined by amino  
25   acid analysis.

#### Example 2

##### (Activity Assay)

            Purified soluble uPAR was biotinylated with NHS-biotin (Molecular Probes) and  
30   immobilized at 0.3 Tg/mL in phosphate-buffered saline (PBS)/0.1% BSA on streptavidin-coated Immulon-2 96-well Removawell plates. Human uPA N-terminal fragment (ATF; from M. Shuman, University of California, San Francisco) was iodinated by the Iodo-Gen method (Pierce). Unincorporated <sup>125</sup>I was separated from labeled protein by Sephadex G-25 chromatography. The specific activity of the labeled protein was between 5 x 10<sup>5</sup> and 1 x  
35   10<sup>6</sup> dpm/mol. The iodinated tracer (100-500 pM) was incubated with the peptides prepared

- 13 -

in Example 1 above in triplicate for 2h at room temperature in PBS/0.1% BSA in a total volume of 200 TL. The plates were washed with PBS/0.1% BSA 3X, and remaining bound radioactivity was measured on an LKB 1277 Gammamaster. Scatchard analysis was performed by using the LIGAND program (Biosoft, Milltown, NJ).

5 The results were as follows:

Seq ID.	Sequence	IC <sub>50</sub> (nM)
1	LNFGQYLWYT	41 ± 17
2	LCFGCYLWYT	35 ± 9
3	LNFGCYLWCT	17 ± 1
4	LNFGQYLnAYT	7 ± 1.2
4	LNFGQYLnAYT	6 ± 1
5	LNFDsQYLWYT	7 ± 3
5	LNFDsQYLWYT	11 ± 3
5	LNFDsQYLWYT	11 ± 2.6
6	LCFGCYLWY	240 ± 37
7	LNFDsQYLnAYT	33 ± 3
8	LNFGdCYLWCT	8 ± 1
8	LNFGdCYLWCT	14 ± 1.5
9	LCFdSCYLWYT	9 ± 1.8
9	LCFdSCYLWYT	23 ± 2.9
10	LCFdSCYLnAYT	79 ± 10
11	LNFDsCYLWCT	225 ± 40

### Example 3

10 (Formulation of huPA Antagonists)

huPA antagonist formulations suitable for use in chemotherapy are prepared as follows:

#### A) Injectable Formulation:

15 LNFGQYLnAYT (SEQ ID NO:4) 25.0 mg  
 Na<sub>2</sub>HPO<sub>4</sub> (0.5 M) 0.5 mL  
 mannitol (25%) 2.5 mL  
 sodium laureate (1%) 2.5 mL  
 pH 7.5  
 20 PBS qs 20.0 mL

This formulation is prepared following the procedure set forth in US 4,816,440, incorporated herein by reference. The formulation is administered by parenteral injection at the site to be treated. The formulation is also generally suitable for administration as

- 14 -

eyedrops directly to the conjunctiva, or by intranasal administration as an aerosol.

Alternatively, a concentrated formulation (e.g., reducing the phosphate buffered saline to 2 mL) may be used to fill an Alzet® minipump, and the minipump implanted at the site to be treated.

5 B) Ophthalmic Preparation:

	LNFGQYLnAYT (SEQ ID NO:4)	1.0 mg
	fibronectin	69.0 mg
	albumin	37.5 mg
	water	qs
10	HCl (0.01 M)	qs
		pH 4.0

This dosage form is prepared following the procedure set forth in US 5,124,155, incorporated herein by reference. The fibronectin and albumin are dissolved in water to form a 3.0 mL solution, and HCl added to a pH of 4.0, causing the fibronectin to flocculate. The  
15 flocculent is filtered, and combined with the peptide. The mixture is then placed in a contact lens mold, and the mold closed for 30 min to form a corneal "shield" in the shape of a contact lens. The shield releases peptide over a period of time, and is useful for preventing angiogenesis of corneal tissue following ophthalmic surgery.

20 The present invention has been described with reference to specific embodiments. However, this application is intended to cover those changes and substitutions which may be made by those skilled in the art without departing from the spirit and the scope of the appended claims.



- 15 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Rosenberg, Steve; Spear, Kerry; Valerio, Robert;  
Bray, Andrew
- 10 (ii) TITLE OF INVENTION: Peptide Analog Inhibitors of Urokinase  
Plasminogen Activator
- (iii) NUMBER OF SEQUENCES: 11
- 15 (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Chiron Corporation  
(B) STREET: 4560 Horton Street  
(C) CITY: Emeryville  
(D) STATE: CA  
(E) COUNTRY: USA  
20 (F) ZIP: 94608
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
25 (B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: US  
30 (B) FILING DATE:  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
35 (A) NAME: Green, Grant D.  
(B) REGISTRATION NUMBER: 31259  
(C) REFERENCE/DOCKET NUMBER: 1118.001
- (ix) TELECOMMUNICATION INFORMATION:  
40 (A) TELEPHONE: 510 6012706  
(B) TELEFAX: 510 655 3542

## (2) INFORMATION FOR SEQ ID NO:1:

- 45 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
50 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 55 (iv) ANTI-SENSE: NO
- 60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
Leu Asn Phe Gly Gln Tyr Leu Trp Tyr Thr

- 16 -

1

5

10

## (2) INFORMATION FOR SEQ ID NO:2:

5

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

15

(iv) ANTI-SENSE: NO

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu	Cys	Phe	Gly	Cys	Tyr	Leu	Trp	Tyr	Thr
1				5					10

25

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

35

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

45

Leu	Asn	Phe	Gly	Cys	Tyr	Leu	Trp	Cys	Thr
1				5					10

## (2) INFORMATION FOR SEQ ID NO:4:

50

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

60

(ix) FEATURE:

- 17 -

(A) NAME/KEY: Modified-site  
(B) LOCATION: 8..9  
(D) OTHER INFORMATION: /product= "OTHER"  
/label= X  
5 /note= "1-naphthylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
10 Leu Asn Phe Gly Gln Tyr Leu Xaa Tyr Thr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
30 (B) LOCATION: 8..9  
(D) OTHER INFORMATION: /product= "OTHER"  
/label= X  
/note= "1-naphthylalanine"

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:  
Leu Asn Phe Gly Gln Tyr Leu Xaa Tyr Thr  
1 5 10

40 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
45 (B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

55 (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 4..5  
(D) OTHER INFORMATION: /product= "OTHER"  
60 /label= d-Ser

- 18 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Leu Asn Phe Xaa Gln Tyr Leu Trp Tyr Thr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Cys Phe Gly Cys Tyr Leu Trp Tyr  
1 5

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: Modified-site  
(B) LOCATION: 5..6  
(D) OTHER INFORMATION: /product= "OTHER"  
/label= X  
/note= "d-cysteine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Asn Phe Gly Xaa Tyr Leu Trp Cys Thr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- 19 -

(ii) MOLECULE TYPE: peptide  
(iii) HYPOTHETICAL: NO  
(iv) ANTI-SENSE: NO  
(ix) FEATURE:  
    (A) NAME/KEY: Modified-site  
    (B) LOCATION: 4..5  
    (D) OTHER INFORMATION: /product= "OTHER"  
/label= S  
/note= "d-Serine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Leu Cys Phe Xaa Cys Tyr Leu Trp Tyr Thr  
1                    5                    10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 11 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:  
    (A) NAME/KEY: Modified-site  
    (B) LOCATION: 4..5  
    (D) OTHER INFORMATION: /product= "OTHER"  
/label= S  
/note= "d-Serine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Leu Cys Phe Xaa Cys Tyr Leu Asn Ala Tyr Thr  
1                    5                    10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 10 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 20 -

## (ix) FEATURE:

5           (A) NAME/KEY: Modified-site  
          (B) LOCATION: 4..5  
          (D) OTHER INFORMATION: /product= "OTHER"  
/label= S  
/note= "d-Serine"

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

15           Leu Asn Phe Xaa Cys Tyr Leu Trp Cys Thr  
          1                   5                   10

- 21 -

WHAT IS CLAIMED:

1. A peptide selected from the group consisting of

LNFGQYLWYT (SEQ ID NO:1),  
LCFGCYLWYT (SEQ ID NO:2),  
LNFGCYLWCT (SEQ ID NO:3),  
LNFGQYL<sub>n</sub>AYT (SEQ ID NO:4),  
LNFdSQYLWYT (SEQ ID NO:5),  
LCFGCYLWY (SEQ ID NO:6),  
LNFdSQYL<sub>n</sub>AYT (SEQ ID NO:7),  
LNFGdCYLWCT (SEQ ID NO:8),  
LCFdSCYLWYT (SEQ ID NO:9),  
LCFdSCYL<sub>n</sub>AYT (SEQ ID NO:10),  
LNFdSCYLWCT (SEQ ID NO:11),

or an active analog thereof.

2. A protein comprising a sequence selected from the group consisting of

LNFGQYLWYT (SEQ ID NO:1),  
LCFGCYLWYT (SEQ ID NO:2),  
LNFGCYLWCT (SEQ ID NO:3),  
LNFGQYL<sub>n</sub>AYT (SEQ ID NO:4),  
LNFdSQYLWYT (SEQ ID NO:5),  
LCFGCYLWY (SEQ ID NO:6),  
LNFdSQYL<sub>n</sub>AYT (SEQ ID NO:7),  
LNFGdCYLWCT (SEQ ID NO:8),  
LCFdSCYLWYT (SEQ ID NO:9),  
LCFdSCYL<sub>n</sub>AYT (SEQ ID NO:10),  
LNFdSCYLWCT (SEQ ID NO:11),

or an active analog thereof.

3. An oligonucleotide which comprises a sequence encoding a peptide selected from the group consisting of

LNFGQYLWYT (SEQ ID NO:1),  
LCFGCYLWYT (SEQ ID NO:2),  
LNFGCYLWCT (SEQ ID NO:3), and  
LCFGCYLWY (SEQ ID NO:6),

or an active analog thereof.

4. A composition useful for treating huPAR-mediated disorders, said

composition comprising:

- 22 -

a pharmaceutically acceptable excipient, and  
an effective amount of a peptide selected from the group consisting of

LNFGQYLWYT (SEQ ID NO:1),  
LCFGCYLWYT (SEQ ID NO:2),  
LNFGCYLWCT (SEQ ID NO:3),  
LNFGQYL<sub>n</sub>AYT (SEQ ID NO:4),  
LNFdSQYLWYT (SEQ ID NO:5),  
LCFGCYLWY (SEQ ID NO:6),  
LNFdSQYL<sub>n</sub>AYT (SEQ ID NO:7),  
LNFGdCYLWCT (SEQ ID NO:8),  
LCFdSCYLWYT (SEQ ID NO:9),  
LCFdSCYL<sub>n</sub>AYT (SEQ ID NO:10), and  
LNFdSCYLWCT (SEQ ID NO:11),

or an active analog thereof.

5. The method of claim 4, wherein said uPA-mediated disorder is selected from the group consisting of metastasis, inappropriate angiogenesis, and chronic inflammation.

6. The method of claim 4, wherein said uPA-mediated disorder is selected from the group consisting of Kaposi's sarcoma, diabetic retinopathy, and rheumatoid arthritis.

7. The method of claim 4, wherein said composition is administered by instillation in the eye.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/12044

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/58 C12N9/72 A61K38/49

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 22464 A (THE GENERAL HOSPITAL CORPORATION) 13 October 1994 see the whole document ---	1-7
X	WO 94 28014 A (CHIRON CORPORATION) 8 December 1994 see the whole document --- -/--	1-7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\* "&amp;" document member of the same patent family

Date of the actual completion of the international search

12 December 1996

Date of mailing of the international search report

20.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Moreau, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/12044

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE BIOSIS  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US  CHUNG S K ET AL: "Inhibition of basic  fibroblast growth factor-induced corneal  angiogenesis by a urokinase plasminogen  activator receptor antagonist."  XP002020944  see abstract  &amp; ANNUAL MEETING OF THE ASSOCIATION FOR  RESEARCH IN VISION AND OPHTHALMOLOGY, FORT  LAUDERDALE, FLORIDA, USA, MAY 14-19, 1995.  INVESTIGATIVE OPHTHALMOLOGY &amp; VISUAL  SCIENCE 36 (4). 1995. S30,</p> <p style="text-align: center;">---</p>	1-7
X	<p>KEYSTONE SYMPOSIUM ON CANCER CELL INVASION  AND MOTILITY, TAMARRON, COLORADO, USA,  FEBRUARY 5-11, 1995. JOURNAL OF CELLULAR  BIOCHEMISTRY SUPPLEMENT 0 (19B). 1995. 27,  XP002020943  MIN H Y ET AL: "Inhibition of primary  tumor growth in syngeneic mice by murine  urokinase receptor antagonists."  see the whole document</p> <p style="text-align: center;">-----</p>	1-7

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/12044

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 5 - 7  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/12044

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9422464	13-10-94	AU-A- 6418794 CA-A- 2159637 EP-A- 0692968 JP-T- 8510207	24-10-94 13-10-94 24-01-96 29-10-96
WO-A-9428014	08-12-94	AU-A- 6954294 CA-A- 2163741 EP-A- 0745092 FI-A- 955720 NO-A- 954722	20-12-94 08-12-94 04-12-96 27-11-95 22-11-95